These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


232 related items for PubMed ID: 11056105

  • 1. Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy.
    Badorff C, Fichtlscherer B, Rhoads RE, Zeiher AM, Muelsch A, Dimmeler S, Knowlton KU.
    Circulation; 2000 Oct 31; 102(18):2276-81. PubMed ID: 11056105
    [Abstract] [Full Text] [Related]

  • 2. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue.
    Badorff C, Berkely N, Mehrotra S, Talhouk JW, Rhoads RE, Knowlton KU.
    J Biol Chem; 2000 Apr 14; 275(15):11191-7. PubMed ID: 10753926
    [Abstract] [Full Text] [Related]

  • 3. Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside.
    Badorff C, Knowlton KU.
    Med Microbiol Immunol; 2004 May 14; 193(2-3):121-6. PubMed ID: 12920582
    [Abstract] [Full Text] [Related]

  • 4. Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice.
    Zell R, Markgraf R, Schmidtke M, Görlach M, Stelzner A, Henke A, Sigusch HH, Glück B.
    Med Microbiol Immunol; 2004 May 14; 193(2-3):91-100. PubMed ID: 14513374
    [Abstract] [Full Text] [Related]

  • 5. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy.
    Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, Knowlton KU.
    Nat Med; 1999 Mar 14; 5(3):320-6. PubMed ID: 10086389
    [Abstract] [Full Text] [Related]

  • 6. Cleavage of osmosensitive transcriptional factor NFAT5 by Coxsackieviral protease 2A promotes viral replication.
    Qiu Y, Ye X, Zhang HM, Hanson P, Zhao G, Tong L, Xie R, Yang D.
    PLoS Pathog; 2017 Dec 14; 13(12):e1006744. PubMed ID: 29220410
    [Abstract] [Full Text] [Related]

  • 7. Selective delivery of nitric oxide to a cellular target: a pseudosubstrate-coupled dinitrosyl-iron complex inhibits the enteroviral protease 2A.
    Badorff C, Fichtlscherer B, Muelsch A, Zeiher AM, Dimmeler S.
    Nitric Oxide; 2002 May 14; 6(3):305-12. PubMed ID: 12009848
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of Coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy.
    Lim BK, Peter AK, Xiong D, Narezkina A, Yung A, Dalton ND, Hwang KK, Yajima T, Chen J, Knowlton KU.
    J Clin Invest; 2013 Dec 14; 123(12):5146-51. PubMed ID: 24200690
    [Abstract] [Full Text] [Related]

  • 9. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy.
    Xiong D, Yajima T, Lim BK, Stenbit A, Dublin A, Dalton ND, Summers-Torres D, Molkentin JD, Duplain H, Wessely R, Chen J, Knowlton KU.
    Circulation; 2007 Jan 02; 115(1):94-102. PubMed ID: 17190866
    [Abstract] [Full Text] [Related]

  • 10. Enteroviral cardiomyopathy: bad news for the dystrophin-glycoprotein complex.
    Badorff C, Lee GH, Knowlton KU.
    Herz; 2000 May 02; 25(3):227-32. PubMed ID: 10904843
    [Abstract] [Full Text] [Related]

  • 11. Dissociation of sarcoglycans and the dystrophin carboxyl terminus from the sarcolemma in enteroviral cardiomyopathy.
    Lee GH, Badorff C, Knowlton KU.
    Circ Res; 2000 Sep 15; 87(6):489-95. PubMed ID: 10988241
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of the catalytic activity of alcohol dehydrogenase by nitric oxide is associated with S nitrosylation and the release of zinc.
    Gergel D, Cederbaum AI.
    Biochemistry; 1996 Dec 17; 35(50):16186-94. PubMed ID: 8973191
    [Abstract] [Full Text] [Related]

  • 13. Critical role of sulfenic acid formation of thiols in the inactivation of glyceraldehyde-3-phosphate dehydrogenase by nitric oxide.
    Ishii T, Sunami O, Nakajima H, Nishio H, Takeuchi T, Hata F.
    Biochem Pharmacol; 1999 Jul 01; 58(1):133-43. PubMed ID: 10403526
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of cathepsin K by nitric oxide donors: evidence for the formation of mixed disulfides and a sulfenic acid.
    Percival MD, Ouellet M, Campagnolo C, Claveau D, Li C.
    Biochemistry; 1999 Oct 12; 38(41):13574-83. PubMed ID: 10521264
    [Abstract] [Full Text] [Related]

  • 15. Nitric oxide and viral cardiomyopathy.
    Finkel MS.
    Circulation; 2000 Oct 31; 102(18):2162-4. PubMed ID: 11056085
    [No Abstract] [Full Text] [Related]

  • 16. Coxsackievirus Protease 2A Targets Host Protease ATG4A to Impair Autophagy.
    Fan YM, Zhang YL, Bahreyni A, Luo H, Mohamud Y.
    Viruses; 2022 Sep 13; 14(9):. PubMed ID: 36146840
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of apoptosis signal-regulating kinase 1 by nitric oxide through a thiol redox mechanism.
    Park HS, Yu JW, Cho JH, Kim MS, Huh SH, Ryoo K, Choi EJ.
    J Biol Chem; 2004 Feb 27; 279(9):7584-90. PubMed ID: 14668338
    [Abstract] [Full Text] [Related]

  • 18. Cleavage and Sub-Cellular Redistribution of Nuclear Pore Protein 98 by Coxsackievirus B3 Protease 2A Impairs Cardioprotection.
    Hanson PJ, Hossain AR, Qiu Y, Zhang HM, Zhao G, Li C, Lin V, Sulaimon S, Vlok M, Fung G, Chen VH, Jan E, McManus BM, Granville DJ, Yang D.
    Front Cell Infect Microbiol; 2019 Feb 27; 9():265. PubMed ID: 31396490
    [Abstract] [Full Text] [Related]

  • 19. An antiviral mechanism of nitric oxide: inhibition of a viral protease.
    Saura M, Zaragoza C, McMillan A, Quick RA, Hohenadl C, Lowenstein JM, Lowenstein CJ.
    Immunity; 1999 Jan 27; 10(1):21-8. PubMed ID: 10023767
    [Abstract] [Full Text] [Related]

  • 20. Nitric oxide donors activate the cyclo-oxygenase and peroxidase activities of prostaglandin H synthase.
    Maccarrone M, Putti S, Finazzi Agrò A.
    FEBS Lett; 1997 Jun 30; 410(2-3):470-6. PubMed ID: 9237685
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.